Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced that it has acquired Rahko, a leading quantum machine learning company, adding powerful new tools to Odyssey’s discovery platform to enable faster and more efficient drug discovery. Rahko was founded in 2018 by Leonard Wossnig, Ph.D., Edward Grant, Ph.D., Miriam Cha, and Ian Horobin, with financing from Balderton Capital. Rahko has built a quantum drug discovery platform that brings together three key technologies—computational chemistry, machine learning, and quantum computing—to drive a better understanding of the behavior of drugs.
Read the full article: Odyssey Therapeutics Acquires Rahko, a Quantum Machine Learning Company //
Source: https://www.prnewswire.com/news-releases/odyssey-therapeutics-acquires-rahko-a-quantum-machine-learning-company-301453689.html